首页 | 本学科首页   官方微博 | 高级检索  
     

奥氮平在精神分裂症中的血清药物浓度/剂量比影响因素研究
引用本文:万 萍,刘 亮,张 萍,张忠东. 奥氮平在精神分裂症中的血清药物浓度/剂量比影响因素研究[J]. 金属学报, 2019, 24(9): 1024-1029. DOI: 10.12092/j.issn.1009-2501.2019.09.010
作者姓名:万 萍  刘 亮  张 萍  张忠东
作者单位:1.南京医科大学附属无锡精神卫生中心药学部,无锡 214151,江苏; ;2.江苏省太湖疗养院,无锡 214086,江苏
基金项目:江苏省卫计委面上项目(Z2017014)
摘    要:目的:探讨影响精神分裂症患者服用奥氮平后血清药物浓度/剂量比(C/D)的因素。方法:回顾性收集了2018年本院304例精神分裂症住院患者的病例资料并查阅入组患者的病历与医嘱,计算奥氮平C/D值,分别考察性别、年龄、BMI、药物来源(国产或进口)、吸烟、合并用药、CYP1A2代谢酶基因型对奥氮平C/D值的影响。结果:男性患者的C/D均值为(2.59±1.08) ng·mL-1·mg-1·d,女性患者的C/D均值为(3.14±1.80) ng·mL-1·mg-1·d,女性患者的C/D均值在统计学上显著高于男性患者的C/D均值(P=0.032)。联合使用肝药酶诱导剂或抑制剂会显著影响患者的C/D值;吸烟会显著降低奥氮平的C/D值(P=0.024);不同年龄与CYP1A2基因型患者的C/D值没有统计学差异;BMI与奥氮平的来源对患者的C/D值没有显著性影响。结论:患者服用奥氮平后的C/D值主要与患者的性别、合并用药以及是否吸烟有关,同时也需要充分考虑患者的基因型。

关 键 词:奥氮平   精神分裂症   血清药物浓度/剂量比   基因型  
收稿时间:2019-04-26
修稿时间:2019-05-20

Influential factors of serum concentration/dosage ratio for schizophrenia patients after oral administration of olanzapine
WAN Ping,LIU Liang,ZHANG Ping,ZHANG Zhongdong. Influential factors of serum concentration/dosage ratio for schizophrenia patients after oral administration of olanzapine[J]. Acta Metallurgica Sinica, 2019, 24(9): 1024-1029. DOI: 10.12092/j.issn.1009-2501.2019.09.010
Authors:WAN Ping  LIU Liang  ZHANG Ping  ZHANG Zhongdong
Affiliation:1.The Affiliated Wuxi Mental Health Center with Nanjing Medical University, Wuxi 214151, Jiangsu, China;2. Taihu Convalescent Hospital, Wuxi 214086, Jiangsu, China
Abstract:AIM: To investigate the factors affecting the serum concentration/dose ratio of olanzapine in schizophrenic patients. METHODS: The data of 304 schizophrenic inpatients in our hospital in 2018 were retrospectively collected, and the patients' medical records and medical orders were consulted. The C/D values of olanzapine were calculated. The effects of gender, age, BMI, source of olanzapine (domestic or imported), smoking, combined use of drugs and CYP1A2 metabolic enzyme genotype polymorphism on the C/D values were studied. RESULTS:The C/D mean value of male patients was (2.59±1.08) ng·mL-1·mg-1·d, and that of female patients was (3.14±1.80) ng·mL-1·mg-1·d. The C/D mean of female patients was significantly higher than that of male patients (P=0.032). The combination of hepatic enzyme inducers or inhibitors could significantly affect the C/D value of patients. Smoking could significantly reduce the C/D value of patients (P=0.024). The C/D value of patients with different ages and CYP1A2 genotype showed no significantly difference. BMI and the source of olanzapine (domestic or imported) had no significant effect on the C/D value of patients. CONCLUSION:The C/D value of olanzapine is mainly related to the gender of patients and the combination of drugs and smoking, and the genotype of patients should be fully considered.
Keywords:olanzapine   schizophrenia   serum drug concentration/dose ratio   genotype  
点击此处可从《金属学报》浏览原始摘要信息
点击此处可从《金属学报》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号